Gilead Sciences (GILD) call put ratio 2.3 calls to 1 put after FT says remdesivir failed in first trial
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
Price: $146.64 -2.88%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -14.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
EPS Growth %: -14.2%
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) 30-day option implied volatility is at 52; compared to its 52-week range of 19 to 108 after FT says remdesivir failed in first trial. Call put ratio 2.3 calls to 1 put.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oracle (ORCL) call put ratio 2.3 calls to 1 put with a focus on October calls into quarter results
- monday.com Ltd. (MNDY) 5400 contracts of November 65 puts trade, share price down 6.6%
- United States Oil Fund (USO) call put ratio 1 call to 1.2 puts as share price up 2.2%
Create E-mail Alert Related Categories
OptionsRelated Entities
OptionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
